PATHOGENESIS OF COVID-19: NEW INSIGHTS
Abstract
Coronavirus disease 2019 (COVID-19), the viral illness caused by the novel coronavirus SARS-CoV-2 has resulted in significant morbidity and mortality across the world since the first cases were identified in Wuhan China, in December 2019. Since then, scientists have been studying the effects of this virus on the human body and its consequences in patients with COVID-19.
References
1.Andersen KG, Rambaut A, Lipkin WI, et al. . The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–452.
2.Anka AU, Tahir MI, Abubakar SD, et al.Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021 Apr;93(4):e12998.
3.Arnold DT, Hamilton FW, Milne A,et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021 Apr;76(4):399-401.
4.Bonaventura A, Vecchié A, Dagna L, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021 May;21(5):319-329.
5.Brancatella A, Ricci D, Viola N, et al. J Clin Endocrinol Metab. 2020 Jul 01;105(7)
6.Cao X. COVID‐19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269‐270.
7.Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–1100.
8.Chippa V, Aleem A, Anjum F. Post Acute Coronavirus (COVID-19) Syndrome. [Updated 2021 Dec 8].
9.Chopra V, Flanders SA, O'Malley M,et al. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021 Apr;174(4):576-578.
10.Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb Pathog. 2021 Jan;150:104673.
11.Douglas D. Richman, Richard J. Whitley & Frederick G. Hayden. Clinical Virology 4th Edition. Washington: ASM Press; 2017.
12.Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID‐19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;201(11):1372‐1379.
13.Fang W, Jiang J, Su L, et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med. 2021 Feb 1;163:153-162.
14.Gamero-de-Luna EJ, Gamero-Estévez E. Mutaciones, variantes y cepas de SARS-CoV-2 [Mutations, variants and strains of SARS-CoV-2]. Semergen. 2021 Apr;47(3):208-209. Spanish.
15. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: Systematic review and meta-analysis. MS Clin Imaging. 2021 Apr; 72(3):75-82
16.Garg M, Maralakunte M, Garg S, et al. The Conundrum of 'Long-COVID-19': A Narrative Review. Int J Gen Med. 2021 Jun 14;14:2491-2506.
17.Garg M, Prabhakar N, Bhalla AS, et al. Review Computed tomography chest in COVID-19: When & why? Indian J Med Res. 2021 Jan & Feb; 153(1 & 2):86-92.
18.Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020 Dec;41(12):1100-1115.
19.Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4; 382(23):2268-2270
20.Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020 Dec;69(12):1181-1189.
21.Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1; 5(7):819-824.
22.Kunnumakkara AB, Rana V, Parama D, et al. COVID-19, cytokines, inflammation, and spices: How are they related? Life Sci. 2021 Nov 1;284:119201.
23.Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 Jun; 7(6):e438-e440.
24.Li, Q. , Guan X., Wu P., et al 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N. Engl. J. Med. 382: 1199–1207.
25.Li YX, Wu W, Yang T, et al. Characteristics of peripheral blood leukocyte differential counts in patients with COVID‐19. Zhonghua Nei Ke Za Zhi. 2020;59:E003
26.Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID‐19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1–7.
27.Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID‐19. Nature. 2020;584(7821):463‐469.
28.Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021 May 12;9(5):497.
29.Mason R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur. Respir. J. 2020;55
30.McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021 Mar; 21(3):313-314.
31.Nägele MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020 Dec;314:58-62.
32.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615.
33.Patient-Led Research Collaborative Report: What Does COVID-19 Recovery Actually Look Like? An Analysis of the Prolonged COVID-19 Symptoms Survey by Patient-Led Research Team. [(accessed on 7 May 2021)];
34.Pekar J, Worobey M, Moshiri N, et al. . Timing the SARS-CoV-2 index case in Hubei Province. bioRxiv. 2020.
35.Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID‐19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
36.Rogers JP, Chesney E, Oliver D, et al. Lancet Psychiatry Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. 2020 Jul; 7(7):611-627.
37.Rubino F, Amiel SA, Zimmet P, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020 Aug 20;383(8):789-790.
38.Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr;87(4):281-286.
39.Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Diehl JL Angiogenesis. 2020 Nov; 23(4):611-620.
40.Sridhar S, Chiu KH, Hung DL et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021 Dec;10(1):507-535.
41.Tabachnikova A, Chen ST. Roles for eosinophils and basophils in COVID‐19? Nat Rev Immunol. 2020;20(8):461.
42.The New York Times Coronavirus Updates: The Illness Now Has a Name, COVID-19. [(accessed on 17 May 2020)];
43.Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418.
44.Wang C., Horby P.W., Hayden F.G., et al. A novel coronavirus outbreak of global health concern. Lancet. 2020
45.Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus‐Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
46.Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study.2020 Aug; 296(2):E55-E64.
47.Wang, Y. , Wang Y., Chen Y., et al 2020. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J. Med. Virol. 92: 568–576.
48.Woodby B, Arnold MM, Valacchi G. SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection? Ann N Y Acad Sci. 2021 Feb;1486(1):15-38.
49.World Health Organization . (2022). WHO Coronavirus Disease (COVID-19) Dashboard. Available at https://covid19.who.int./. Accessed 06 February 2022.
50.Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265‐269.
51.Wu, Z. & McGoogan J.M.. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323: 1239–1242.
52.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID‐19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420‐422.
53.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
54.Ziegler C.G.K., Allon S.J., Nyquist S.K. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035 e1019.
